Hikma Pharmaceuticals reported a 14% revenue increase in 2023 to $2.875 billion, driven by growth in Injectables, Branded, and Generics businesses.
Hikma Pharmaceuticals reported a 14% revenue increase in 2023, reaching $2.875 billion. The company's three businesses - Injectables, Branded, and Generics - experienced growth driven by new launches, partnerships, and expanded portfolios. Injectables revenue grew 6% to $1.203 billion, Branded revenue increased 3% to $714 million, and Generics revenue soared 39% to $937 million. Hikma anticipates Group revenue growth of 4% to 6% in 2024.
February 22, 2024
8 Articles